DMD Celsis microsomes mean better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prueksaritanont, T.
Right arrow Articles by Lin, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prueksaritanont, T.
Right arrow Articles by Lin, J. H.

Vol. 26, Issue 6, 520-527, June 1998

In Vitro and In Vivo Evaluations of Intestinal Barriers for the Zwitterion L-767,679 and Its Carboxyl Ester Prodrug L-775,318
Roles of Efflux and Metabolism

Thomayant Prueksaritanont, Polly DeLuna, Lynn M. Gorham, Bennett Ma, Dosinda Cohn, Jianmei Pang, Xin Xu, Kwan Leung, and Jiunn H. Lin

Department of Drug Metabolism, Merck Research Laboratories

The barriers to oral delivery of the hydrophilic zwitterion L-767,679 (I) and its carboxyl ester prodrug L-775,318 (II) were examined. In the Caco-2 cell model, transport of II, but not I, was strongly oriented in the secretory direction. The basal-to-apical transport of II displayed saturable kinetics and was markedly inhibited by verapamil and quinidine, known P-glycoprotein inhibitors. In Caco-2 cells, metabolism of I was not observed, whereas hydrolysis of II was modest (<= 20%). In the in situ rat intestinal loop model, verapamil did not affect the absorption of I but significantly increased the absorption of II. I was resistant to intestinal metabolism, whereas II underwent hydrolysis partially in rat lumen but more extensively in rat intestinal tissue and blood. In vitro metabolism studies indicated that verapamil also inhibited the hydrolysis of II in rats. The inhibition was relatively specific for the intestinal and not the luminal esterases. These results suggested that the intestinal absorption of I was limited not by intestinal efflux or metabolism but more likely by the low lipophilicity of I. However, an efflux system, likely mediated by P-glycoprotein, played an important role in limiting the absorption of II. In rats, metabolism served as an additional barrier to the absorption of II. Verapamil increased the intestinal absorption of the prodrug by inhibiting the efflux system in the two models studied, as well as possibly inhibiting metabolism in rats. For the first time, secretory transport was identified as a cause of the failure to increase the absorption of a lipophilic and cationic prodrug developed to overcome the absorption problem.


Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K. Masaki, M. Hashimoto, and T. Imai
Intestinal First-Pass Metabolism via Carboxylesterase in Rat Jejunum and Ileum
Drug Metab. Dispos., July 1, 2007; 35(7): 1089 - 1095.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. Masaki, M. Taketani, and T. Imai
FIRST-PASS HYDROLYSIS OF A PROPRANOLOL ESTER DERIVATIVE IN RAT SMALL INTESTINE
Drug Metab. Dispos., March 1, 2006; 34(3): 398 - 404.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Okudaira, I. Komiya, and Y. Sugiyama
Polarized Efflux of Mono- and Diacid Metabolites of ME3229, an Ester-Type Prodrug of a Glycoprotein IIb/IIIa Receptor Antagonist, in Rat Small Intestine
J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 717 - 723.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Okudaira, T. Tatebayashi, G. C. Speirs, I. Komiya, and Y. Sugiyama
A Study of the Intestinal Absorption of an Ester-Type Prodrug, ME3229, in Rats: Active Efflux Transport as a Cause of Poor Bioavailability of the Active Drug
J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 580 - 587.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.